Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Cellular Oncology
Erschienen in:

18.03.2021 | Review

3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment

verfasst von: Mingxue Li, Canrong Wu, Yueying Yang, Mengzhu Zheng, Silin Yu, Jinhui Wang, Lixia Chen, Hua Li

Erschienen in: Cellular Oncology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Metabolic changes have been recognized as an important hallmark of cancer cells. Cancer cells can promote their own growth and proliferation through metabolic reprogramming. Particularly, serine metabolism has frequently been reported to be dysregulated in tumor cells. 3-Phosphoglycerate dehydrogenase (PHGDH) catalyzes the first step in the serine biosynthesis pathway and acts as a rate-limiting enzyme involved in metabolic reprogramming. PHGDH upregulation has been observed in many tumor types, and inhibition of PHGDH expression has been reported to inhibit the proliferation of PHGDH-overexpressing tumor cells, indicating that it may be utilized as a target for cancer treatment. Recently identified inhibitors targeting PHGDH have already shown effectiveness. A further in-depth analysis and concomitant development of PHGDH inhibitors will be of great value for the treatment of cancer.

Conclusions

In this review we describe in detail the role of PHGDH in various cancers and inhibitors that have recently been identified to highlight progression in cancer treatment. We also discuss the development of new drugs and treatment modalities based on PHGDH targets. Overexpression of PHGDH has been observed in melanoma, breast cancer, nasopharyngeal carcinoma, parathyroid adenoma, glioma, cervical cancer and others. PHGDH may serve as a molecular biomarker for the diagnosis, prognosis and treatment of these cancers. The design and development of novel PHGDH inhibitors may have broad implications for cancer treatment. Therapeutic strategies of PHGDH inhibitors in combination with traditional chemotherapeutic drugs may provide new perspectives for precision medicine and effective personalized treatment for cancer patients.

Graphical abstract

Literatur
1.
G.A. Barker, J.C. Ellory, The identification of neutral amino acid transport systems. Exp. Physiol. 75, 3–26 (1990)PubMedCrossRef
2.
M. Palacín, R. Estévez, J. Bertran, A. Zorzano, Molecular biology of mammalian plasma membrane amino acid transporters. Physiol. Rev. 78, 969–1054 (1998)PubMedCrossRef
3.
C.F. Labuschagne, N.J. van den Broek, G.M. Mackay, K.H. Vousden, O.D. Maddocks, Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. Cell Rep. 7(4), 1248–1258 (2014)PubMedCrossRef
4.
5.
M.R. Sullivan, K.R. Mattaini, E.A. Dennstedt, A.A. Nguyen, S. Sivanand, M.F. Reilly, K. Meeth, A. Muir, A.M. Darnell, M.W. Bosenberg, C.A. Lewis, M.G. Vander Heiden, Increased serine synthesis provides an advantage for tumors arising in tissues where serine levels are limiting. Cell Metab. 29, 1410–1421 (2019)PubMedPubMedCentralCrossRef
6.
7.
K. Snell, Y. Natsumeda, G. Weber, The modulation of serine metabolism in hepatoma 3924A during different phases of cellular proliferation in culture. Biochem. J. 245, 609–612 (1987)PubMedPubMedCentralCrossRef
8.
9.
E. Gottlieb, I.P. Tomlinson, Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 5(11), 857–866 (2005)PubMedCrossRef
10.
S.G. Dann, R.T. Abraham, Serine biosynthesis: fuel for the melanoma cell growth engine. Pigment Cell Melanoma Res. 24, 875–877 (2011)PubMedCrossRef
11.
E. Mullarky, L.L. Lairson, L.C. Cantley, C.A. Lyssiotis, A novel small-molecule inhibitor of 3-phosphoglycerate dehydrogenase. Mol. Cell. Oncol. 3, e1164280 (2016)
12.
13.
E. Mullarky, K.R. Mattaini, M.G. Vander Heiden, L.C. Cantley, J.W. Locasale, PHGDH amplification and altered glucose metabolism in human melanoma. Pigment Cell Melanoma Res. 24, 1112–1115 (2011)PubMedCrossRef
14.
I. Kraoua, E. Wiame, L. Kraoua, F. Nasrallah, H. Benrhouma, A. Rouissi, I. Turki, H. Chaabouni, G. Briand, N. Kaabachi, E. Van Schaftingen, N. Gouider-Khouja, 3-Phosphoglycerate dehydrogenase deficiency: description of two new cases in Tunisia and review of the literature. Neuropediatrics 44(5), 281–285 (2013)PubMedCrossRef
15.
16.
17.
J.E. Unterlass, N.J. Curtin, Warburg and Krebs and related effects in cancer. Expert Rev. Mol. Med. 21, e4 (2019)
18.
R.A. Cairns, I.S. Harris, T.W. Mak, Regulation of cancer cell metabolism. Nat. Rev. Cancer 11(2), 85–95 (2011)PubMedCrossRef
19.
O. Warburg, Über den stoffwechsel der carcinom-zelle. J. Mol. Med. 4(12), 534–536 (1925)
20.
21.
O. Warburg, K. Posener, E. Negelein, Ueber den stoffwechsel der tumoren. Biochem. Z. 152, 319–344 (1924)
22.
S.Y. Lunt, M.G. Vander Heiden, Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27, 441–464 (2011)PubMedCrossRef
23.
I. Amelio, F. Cutruzzolá, A. Antonov, M. Agostini, G. Melino, Serine and glycine metabolism in cancer. Trends Biochem. Sci. 39, 191–198 (2014)PubMedPubMedCentralCrossRef
24.
25.
P.M. Tedeschi, E.K. Markert, M. Gounder, H. Lin, D. Dvorzhinski, S.C. Dolfi, L.L. Chan, J. Qiu, R.S. DiPaola, K.M. Hirshfield, L.G. Boros, J.R. Bertino, Z.N. Oltvai, A. Vazquez, Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell Death Dis. 4, e877 (2013)
26.
R.J. DeBerardinis, T. Cheng, Q’s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29(3), 313–324 (2010)PubMedCrossRef
27.
28.
29.
O. Kuge, K. Hasegawa, K. Saito, M. Nishijima, Control of phosphatidylserine biosynthesis through phosphatidylserine-mediated inhibition of phosphatidylserine synthase I in Chinese hamster ovary cells. Proc. Natl. Acad. Sci. U. S. A. 95, 4199–4203 (1998)
30.
31.
A.H. Futerman, H. Riezman, The ins and outs of sphingolipid synthesis. Trends Cell Biol. 15, 312–318 (2005)PubMedCrossRef
32.
M. Yang, K.H. Vousden, Serine and one-carbon metabolism in cancer. Nat. Rev. Cancer 16(10), 650–662 (2016)PubMedCrossRef
33.
J.S. Metcalf, R.A. Dunlop, J.T. Powell, S.A. Banack, P.A. Cox, L-serine: a naturally-occurring amino acid with therapeutic potential. Neurotox. Res. 33, 213–221 (2018)PubMedCrossRef
34.
K. Okabe, I. Usui, K. Yaku, Y. Hirabayashi, K. Tobe, T. Nakagawa, Deletion of PHGDH in adipocytes improves glucose intolerance in diet-induced obese mice. Biochem. Biophys. Res. Commun. 504, 309–314 (2018)PubMedCrossRef
35.
S. Vandekeere, C. Dubois, J. Kalucka, M.R. Sullivan, M. García-Caballero, J. Goveia, R. Chen, F.F. Diehl, L. Bar-Lev, J. Souffreau, A. Pircher, S. Kumar, S. Vinckier, Y. Hirabayashi, S. Furuya, L. Schoonjans, G. Eelen, B. Ghesquière, E. Keshet, X. Li, M.G. Vander Heiden, M. Dewerchin, P. Carmeliet, Serine synthesis via PHGDH is essential for heme production in endothelial cells. Cell Metab. 28, 573–587 (2018)PubMedCrossRef
36.
A. Schulze, A.L. Harris, How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 491, 364–373 (2012)PubMedCrossRef
37.
E. Piskounova, M. Agathocleous, M.M. Murphy, Z. Hu, S.E. Huddlestun, Z. Zhao, A.M. Leitch, T.M. Johnson, R.J. DeBerardinis, S.J. Morrison, Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527, 186–191 (2015)PubMedPubMedCentralCrossRef
38.
E. Mullarky, L.C. Cantley, Diverting glycolysis to combat oxidative stress. (Springer, Tokyo, 2015), pp. 3–23
39.
J. Ye, J. Fan, S. Venneti, Y.W. Wan, B.R. Pawel, J. Zhang, L.W. Finley, C. Lu, T. Lindsten, J.R. Cross, G. Qing, Z. Liu, M.C. Simon, J.D. Rabinowitz, C.B. Thompson, Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov. 4, 1406–1417 (2014)PubMedPubMedCentralCrossRef
40.
J.W. Locasale, A.R. Grassian, T. Melman, C.A. Lyssiotis, K.R. Mattaini, A.J. Bass, G. Heffron, C.M. Metallo, T. Muranen, H. Sharfi, A.T. Sasaki, D. Anastasiou, E. Mullarky, N.I. Vokes, M. Sasaki, R. Beroukhim, G. Stephanopoulos, A.H. Ligon, M. Meyerson, A.L. Richardson, L. Chin, G. Wagner, J.M. Asara, J.S. Brugge, L.C. Cantley, M.G. Vander Heiden, Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 43, 869–874 (2011)PubMedPubMedCentralCrossRef
41.
R. Possemato, K.M. Marks, Y.D. Shaul, M.E. Pacold, D. Kim, K. Birsoy, S. Sethumadhavan, H.K. Woo, H.G. Jang, A.K. Jha, W.W. Chen, F.G. Barrett, N. Stransky, Z.Y. Tsun, G.S. Cowley, J. Barretina, N.Y. Kalaany, P.P. Hsu, K. Ottina, A.M. Chan, B. Yuan, L.A. Garraway, D.E. Root, M. Mino-Kenudson, E.F. Brachtel, E.M. Driggers, D.M. Sabatini, Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346–350 (2011)PubMedPubMedCentralCrossRef
42.
D. Samanta, Y. Park, S.A. Andrabi, L.M. Shelton, D.M. Gilkes, G.L. Semenza, PHGDH expression is required for mitochondrial redox homeostasis, breast cancer stem cell maintenance, and lung metastasis. Cancer Res. 76, 4430–4442 (2016)PubMedCrossRef
43.
S. Pollari, S.M. Käkönen, H. Edgren, M. Wolf, P. Kohonen, H. Sara, T. Guise, M. Nees, O. Kallioniemi, Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Res. Treat. 125, 421–430 (2011)PubMedCrossRef
44.
G.M. DeNicola, P.H. Chen, E. Mullarky, J.A. Sudderth, Z. Hu, D. Wu, H. Tang, Y. Xie, J.M. Asara, K.E. Huffman, I.I. Wistuba, J.D. Minna, R.J. DeBerardinis, L.C. Cantley, Erratum: NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat. Genet. 48, 473 (2016)
45.
S. Ravez, Q. Spillier, R. Marteau, O. Feron, R. Frédérick, Challenges and opportunities in the development of serine synthetic pathway inhibitors for cancer therapy. J. Med. Chem. 60, 1227–1237 (2017)PubMedCrossRef
46.
K. Snell, Enzymes of serine metabolism in normal, developing and neoplastic rat tissues. Adv. Enzyme Regul. 22, 325–400 (1984)PubMedCrossRef
47.
K. Snell, Enzymes of serine metabolism in normal and neoplastic rat tissues. Biochim. Biophys. Acta 843, 276–281 (1985)PubMedCrossRef
48.
K. Snell, The duality of pathways for serine biosynthesis is a fallacy. Trends Biochem. Sci. 11, 241–243 (1986)CrossRef
49.
D.A. Walsh, H.J. Sallach, Comparative studies on the pathways for serine biosynthesis in animal tissues. J. Biol. Chem. 241, 4068–4076 (1966)PubMedCrossRef
50.
G.P. Cheung, J. Cotropia, H.J. Sallach, The effects of dietary protein on the hepatic enzymes of serine metabolism in the rabbit. Arch. Biochem. Biophys. 129, 672–682 (1969)PubMedCrossRef
51.
E.V. Rowsell, K. Snell, J.A. Carnie, A.H. Al-Tai, Liver-L-alanine-glyoxylate and L-serine-pyruvate aminotransferase activities: an apparent association with gluconeogenesis. Biochem. J. 115, 1071–1073 (1969)PubMedPubMedCentralCrossRef
52.
P. Stover, V. Schirch, Serine hydroxymethyltransferase catalyzes the hydrolysis of 5,10-methenyltetrahydrofolate to 5-formyltetrahydrofolate. J. Biol. Chem. 265, 14227–14233 (1990)PubMedCrossRef
53.
A.S. Tibbetts, D.R. Appling, R. Appling Dean, Compartmentalization of Mammalian folate-mediated one-carbon metabolism. Annu. Rev. Nutr. 30, 57–81 (2010)PubMedCrossRef
54.
M.G. Vander Heiden, J.W. Locasale, K.D. Swanson, H. Sharfi, G.J. Heffron, D. Amador-Noguez, H.R. Christofk, G. Wagner, J.D. Rabinowitz, J.M. Asara, L.C. Cantley, Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329, 1492–1499 (2010)PubMedCrossRef
55.
56.
L. Sun, L. Song, Q. Wan, G. Wu, X. Li, Y. Wang, J. Wang, Z. Liu, X. Zhong, X. He, S. Shen, X. Pan, A. Li, Y. Wang, P. Gao, H. Tang, H. Zhang, cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions. Cell Res. 25(4), 429–444 (2015)PubMedPubMedCentralCrossRef
57.
G.A. Grant, A new family of 2-hydroxyacid dehydrogenases. Biochem. Biophys. Res. Commun. 165, 1371–1374 (1989)PubMedCrossRef
58.
C. Vinals, E. Depiereux, E. Feytmans, Prediction of structurally conserved regions of D-specific hydroxy acid dehydrogenases by multiple alignment with formate dehydrogenase. Biochem. Biophys. Res. Commun. 192, 182–188 (1993)PubMedCrossRef
59.
D.M. Greenberg, A. Ichihara, Further studies on the pathway of serine formation from carbohydrate. J. Biol. Chem. 224(1), 331–340 (1957)PubMedCrossRef
60.
J.D. Goldberg, T. Yoshida, P. Brick, Crystal structure of a NAD-dependent D-glycerate dehydrogenase at 2.4 Å resolution. J. Mol. Biol. 236, 1123–1140 (1994)PubMedCrossRef
61.
V.S. Lamzin, Z. Dauter, V.O. Popov, E.H. Harutyunyan, K.S. Wilson, High resolution structures of holo and apo formate dehydrogenase. J. Mol. Biol. 236, 759–785 (1994)PubMedCrossRef
62.
A. Ichihara, D.M. Greenberg, Studies on the purification and properties of D-glyceric acid kinase of liver. J. Biol. Chem. 225, 949–958 (1957)PubMedCrossRef
63.
J.E. Willis, H.J. Sallach, The occurrence of D-3-phosphoglycerate dehydrogenase in animal tissue. Biochim. Biophys. Acta 81(1), 39–54 (1964)
64.
M.O. Kinoshita, Y. Shinoda, K. Sakai, T. Hashikawa, M. Watanabe, T. Machida, Y. Hirabayashi, S. Furuya, Selective upregulation of 3-phosphoglycerate dehydrogenase (PHGDH) expression in adult subventricular zone neurogenic niche. Neurosci. Lett. 453, 21–26 (2009)PubMedCrossRef
65.
L.W. Klomp, T.J. de Koning, H.E. Malingré, E.A. van Beurden, M. Brink, F.L. Opdam, M. Duran, J. Jaeken, M. Pineda, L. Van Maldergem, B.T. Poll-The, I.E. van den Berg, R. Berger, Molecular characterization of 3-phosphoglycerate dehydrogenase deficiency-a neurometabolic disorder associated with reduced L-serine biosynthesis. Am. J. Hum. Genet. 67, 1389–1399 (2000)PubMedPubMedCentralCrossRef
66.
K. Yoshida, S. Furuya, S. Osuka, J. Mitoma, Y. Shinoda, M. Watanabe, N. Azuma, H. Tanaka, T. Hashikawa, S. Itohara, Y. Hirabayashi, Targeted disruption of the mouse 3-phosphoglycerate dehydrogenase gene causes severe neurodevelopmental defects and results in embryonic lethality. J. Biol. Chem. 279, 3573–3577 (2004)PubMedCrossRef
67.
S. Furuya, T. Tabata, J. Mitoma, K. Yamada, M. Yamasaki, A. Makino, T. Yamamoto, M. Watanabe, M. Kano, Y. Hirabayashi, L-serine and glycine serve as major astroglia-derived trophic factors for cerebellar purkinje neurons. Proc. Natl. Acad. Sci. U. S. A. 97, 11528–11533 (2000)
68.
K. Yamasaki, K. Yamada, S. Furuya, J. Mitoma, Y. Hirabayashi, Y. Watanabe, 3-Phosphoglycerate dehydrogenase (3PGDH), a key enzyme for L-serine biosynthesis, is preferentially expressed in the radial glia/astrocyte lineage and olfactory ensheathing glia in the mouse brain. J. Neurosci. 21, 7691–7704 (2001)PubMedPubMedCentralCrossRef
69.
Y. Achouri, M.H. Rider, E.V.V. Schaftingen, M. Robbi, Cloning, sequencing and expression of rat liver 3-phosphoglycerate dehydrogenase. Biochem. J. 323(2), 365–370 (1997)PubMedPubMedCentralCrossRef
70.
K.L. Tobey, G.A. Grant, The nucleotide sequence of the serA gene of Escherichia coli and the amino acid sequence of the encoded protein, D-3-phosphoglycerate dehydrogenase. J. Biol. Chem. 261, 12179–12183 (1986)PubMedCrossRef
71.
R.D. Fleischmann, M.D. Adams, O. White, R.A. Clayton, E.F. Kirkness, A.R. Kerlavage, C.J. Bult, J.F. Tomb, B.A. Dougherty, J.M. Merrick, Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269, 496–512 (1995)PubMedCrossRef
72.
A. Sorokin, E. Zumstein, V. Azevedo, S.D. Ehrlich, P. Serror, The organization of the Bacillus subtilis 168 chromosome region between the spoVA and serA genetic loci, based on sequence data. Mol. Microbiol. 10, 385–395 (1993)PubMedCrossRef
73.
H.M. Cho, D.Y. Jun, M.A. Bae, Y.H. Kim, Nucleotide sequence and differential expression of the human 3-phosphoglycerate dehydrogenase gene. Gene 245, 193–201 (2000)PubMedCrossRef
74.
R. Wilson, R. Ainscough, K. Anderson, C. Baynes, M. Berks, J. Bonfield, J. Burton, M. Connell, T. Copsey, J. Cooper, 2.2 Mb of contiguous nucleotide sequence from chromosome III of C. elegans. Nature 368, 32–38 (1994)
75.
J. Mitoma, S. Furuya, M. Shimizu, Y. Shinoda, K. Yoshida, N. Azuma, H. Tanaka, Y. Suzuki, Y. Hirabayashi, Mouse 3-phosphoglycerate dehydrogenase gene: genomic organization, chromosomal localization, and promoter analysis. Gene 334, 15–22 (2004)PubMedCrossRef
76.
M. Robbi, Y. Achouri, C. Szpirer, E. Van Schaftingen, The gene encoding rat 3-phosphoglycerate dehydrogenase. Mamm. Genome 11, 1034–1036 (2000)PubMedCrossRef
77.
S. Dey, Z. Hu, X.L. Xu, J.C. Sacchettini, G.A. Grant, D-3-Phosphoglycerate dehydrogenase from Mycobacterium tuberculosis is a link between the Escherichia coli and mammalian enzymes. J. Biol. Chem. 280, 14884–14891 (2005)PubMedCrossRef
78.
J.E. Unterlass, R.J. Wood, A. Baslé, J. Tucker, C. Cano, M.M.E. Noble, N.J. Curtin, Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH). Oncotarget 8, 104478–104491 (2017)PubMedPubMedCentralCrossRef
79.
S. Dey, G.A. Grant, J.C. Sacchettini, Crystal structure of Mycobacterium tuberculosis D-3-phosphoglycerate dehydrogenase: extreme asymmetry in a tetramer of identical subunits. J. Biol. Chem. 280, 14892–14899 (2005)PubMedCrossRef
80.
D.J. Schuller, G.A. Grant, L.J. Banaszak, The allosteric ligand site in the Vmax-type cooperative enzyme phosphoglycerate dehydrogenase. Nat. Struct. Biol. 2, 69–76 (1995)PubMedCrossRef
81.
V. Truong, S. Huang, J. Dennis, M. Lemire, N. Zwingerman, D. Aïssi, I. Kassam, C. Perret, P. Wells, P.E. Morange, M. Wilson, D.A. Trégouët, F. Gagnon, Blood triglyceride levels are associated with DNA methylation at the serine metabolism gene PHGDH. Sci. Rep. 7, 11207 (2017)PubMedPubMedCentralCrossRef
82.
R. Shaheen, Z. Rahbeeni, A. Alhashem, E. Faqeih, Q. Zhao, Y. Xiong, A. Almoisheer, S.M. Al-Qattan, H.A. Almadani, N. Al-Onazi, B.S. Al-Baqawi, M.A. Saleh, F.S. Alkuraya, Neu-Laxova syndrome, an inborn error of serine metabolism, is caused by mutations in PHGDH. Am. J. Hum. Genet. 94, 898–904 (2014)PubMedPubMedCentralCrossRef
83.
D.J. Xiang, H.P. Yan, Q. Xin, F. Lu, X. Feng, Y. Zhao, Y. Liu, J.X. Yang, Cloning and expression of 3-phosphoglycerate dehydrogenase gene and its correlative antibodies in diagnosis of autoimmune hepatitis. Zhonghua Gan Zang Bing Za Zhi 17, 378–382 (2009)PubMed
84.
J. Chen, F. Chung, G. Yang, M. Pu, H. Gao, W. Jiang, H. Yin, V. Capka, S. Kasibhatla, B. Laffitte, S. Jaeger, R. Pagliarini, Y. Chen, W. Zhou, Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth. Oncotarget 4, 2502–2511 (2013)PubMedPubMedCentralCrossRef
85.
R.B. Hamanaka, R. Nigdelioglu, A.Y. Meliton, Y. Tian, L.J. Witt, E. O’Leary, K.A. Sun, P.S. Woods, D. Wu, B. Ansbro, S. Ard, J.M. Rohde, N.O. Dulin, R.D. Guzy, G.M. Mutlu, Inhibition of phosphoglycerate dehydrogenase attenuates bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 58, 585–593 (2018)PubMedPubMedCentralCrossRef
86.
H. Yoshino, N. Nohata, K. Miyamoto, M. Yonemori, T. Sakaguchi, S. Sugita, T. Itesako, S. Kofuji, M. Nakagawa, R. Dahiya, H. Enokida, PHGDH as a key enzyme for serine biosynthesis in HIF2α-targeting therapy for renal cell carcinoma. Cancer Res. 77, 6321–6329 (2017)PubMedPubMedCentralCrossRef
87.
B. Zhang, A. Zheng, P. Hydbring, G. Ambroise, A.T. Ouchida, M. Goiny, H. Vakifahmetoglu-Norberg, E. Norberg, PHGDH defines a metabolic subtype in lung adenocarcinomas with poor prognosis. Cell Rep. 19, 2289–2303 (2017)PubMedCrossRef
88.
A.L. Engel, N.I. Lorenz, K. Klann, C. Münch, C. Depner, J.P. Steinbach, M.W. Ronellenfitsch, A.L. Luger, Serine-dependent redox homeostasis regulates glioblastoma cell survival. Br. J. Cancer 122(9), 1391–1398 (2020)PubMedPubMedCentralCrossRef
89.
X.Q. Jia, S. Zhang, H.J. Zhu, W. Wang, J.H. Zhu, X.D. Wang, J.F. Qiang, Increased expression of PHGDH and prognostic significance in colorectal cancer. Transl. Oncol. 9, 191–196 (2016)PubMedPubMedCentralCrossRef
90.
91.
K. Snell, Y. Natsumeda, J.N. Eble, J.L. Glover, G. Weber, Enzymic imbalance in serine metabolism in human colon carcinoma and rat sarcoma. Br. J. Cancer. 57, 87–90 (1988)PubMedPubMedCentralCrossRef
92.
S. Noh, D.H. Kim, W.H. Jung, J.S. Koo, Expression levels of serine/glycine metabolism-related proteins in triple negative breast cancer tissues. Tumour Biol. 35, 4457–4468 (2014)PubMedCrossRef
93.
X. Zhang, W. Bai, Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin. Cancer Chemother. Pharmacol. 78, 655–659 (2016)PubMedCrossRef
94.
J. Fan, X. Teng, L. Liu, K.R. Mattaini, R.E. Looper, M.G. Vander Heiden, J.D. Rabinowitz, Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate. ACS Chem. Biol. 10, 510–516 (2015)PubMedCrossRef
95.
K.R. Mattaini, M.R. Sullivan, A.N. Lau, B.P. Fiske, R.T. Bronson, M.G. Vander Heiden, Increased PHGDH expression promotes aberrant melanin accumulation. BMC Cancer 19, 723 (2019)PubMedPubMedCentralCrossRef
96.
Y. Ou, S.J. Wang, L. Jiang, B. Zheng, W. Gu, p53 protein-mediated regulation of phosphoglycerate dehydrogenase (PHGDH) is crucial for the apoptotic response upon serine starvation. J. Biol. Chem. 290, 457–466 (2015)PubMedCrossRef
97.
J. Liu, S. Guo, Q. Li, L. Yang, Z. Xia, L. Zhang, Z. Huang, N. Zhang, Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1. J. Neurooncol. 111, 245–255 (2013)PubMedCrossRef
98.
Z. Jing, W. Heng, D. Aiping, Q. Yafei, Z. Shulan, Expression and clinical significance of phosphoglycerate dehydrogenase and squamous cell carcinoma antigen in cervical cancer. Int. J. Gynecol. Cancer 23, 1465–1469 (2013)PubMedCrossRef
99.
Z. Jing, W. Heng, L. Xia, W. Ning, Q. Yafei, Z. Yao, Z. Shulan, Downregulation of phosphoglycerate dehydrogenase inhibits proliferation and enhances cisplatin sensitivity in cervical adenocarcinoma cells by regulating Bcl-2 and caspase-3. Cancer Biol. Ther. 16, 541–548 (2015)PubMedPubMedCentralCrossRef
100.
J. Zhu, J. Ma, X. Wang, T. Ma, S. Zhang, W. Wang, X. Zhou, J. Shi, High Expression of PHGDH predicts poor prognosis in non-small cell lung cancer. Transl. Oncol. 9, 592–599 (2016)PubMedPubMedCentralCrossRef
101.
X. Ma, B. Li, J. Liu, Y. Fu, Y. Luo, Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E. J. Exp. Clin. Cancer Res. 38, 66 (2019)
102.
Z. Song, C. Feng, Y. Lu, Y. Lin, C. Dong, PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer. Gene 642, 43–50 (2018)PubMedCrossRef
103.
Y. Xian, S. Zhang, X. Wang, J. Qin, W. Wang, H. Wu, Phosphoglycerate dehydrogenase is a novel predictor for poor prognosis in gastric cancer. Onco. Targets Ther. 9, 5553–5560 (2016)PubMedPubMedCentralCrossRef
104.
A. Fenner, Kidney cancer: PHGDH is key for targeting HIF in RCC. Nat. Rev. Urol. 14, 702 (2017)PubMedCrossRef
105.
Y. Ye, Y. Zhou, L. Zhang, Y. Chen, X. Lyu, L. Cai, Y. Lu, Y. Deng, J. Wang, K. Yao, W. Fang, H. Cai, X. Li, EBV-miR-BART1 is involved in regulating metabolism-associated genes in nasopharyngeal carcinoma. Biochem. Biophys. Res. Commun. 436, 19–24 (2013)PubMedCrossRef
106.
W.Y. Sun, H.M. Kim, W.H. Jung, J.S. Koo, Expression of serine/glycine metabolism-related proteins is different according to the thyroid cancer subtype. J. Transl. Med. 14, 168 (2016)PubMedPubMedCentralCrossRef
107.
J. Wang, H. Ni, L. Chen, Y.X. Liu, C.B. Chen, W.Q. Song, Preparation and analysis of cSNP chip on hepatocellular carcinoma-related genes. HBPD Int. 4, 398–402 (2005)PubMed
108.
L. Wei, D. Lee, C.T. Law, M.S. Zhang, J. Shen, D.W. Chin, A. Zhang, F.H. Tsang, C.L. Wong, I.O. Ng, C.C. Wong, C.M. Wong, Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nat. Commun. 10, 4681 (2019)PubMedPubMedCentralCrossRef
109.
J.K. Dong, H.M. Lei, Q. Liang, Y.B. Tang, Y. Zhou, Y. Wang, S. Zhang, W.B. Li, Y. Tong, G. Zhuang, L. Zhang, H.Z. Chen, L. Zhu, Y. Shen, Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase. Theranostics 8, 1808–1823 (2018)PubMedPubMedCentralCrossRef
110.
S. Yoon, J.G. Kim, A.N. Seo, S.Y. Park, H.J. Kim, J.S. Park, G.S. Choi, J.Y. Jeong, Y. Jun do, G.S. Yoon, B.W. Kang, Clinical implication of serine metabolism-associated enzymes in colon cancer. Oncology 89, 351–359 (2015)
111.
F. Polet, C. Corbet, A. Pinto, L.I. Rubio, R. Martherus, V. Bol, X. Drozak, V. Grégoire, O. Riant, O. Feron, Reducing the serine availability complements the inhibition of the glutamine metabolism to block leukemia cell growth. Oncotarget 7, 1765–1776 (2016)PubMedCrossRef
112.
X. Wu, J. Xia, J. Zhang, Y. Zhu, Y. Wu, J. Guo, S. Chen, Q. Lei, B. Meng, C. Kuang, X. Feng, Y. He, Y. Shen, X. Li, L. Qiu, G. Li, W. Zhou, Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma. Br. J. Haematol. 190, 52–66 (2020)PubMedCrossRef
113.
A. Palermo, M. Fosca, G. Tabacco, F. Marini, V. Graziani, M.C. Santarsia, F. Longo, A. Lauria, R. Cesareo, I. Giovannoni, C. Taffon, M. Rocchia, S. Manfrini, P. Crucitti, P. Pozzilli, A. Crescenzi, J.V. Rau, Raman spectroscopy applied to parathyroid tissues: a new diagnostic tool to discriminate normal tissue from adenoma. Anal. Chem. 90(1), 847–854 (2018)PubMedCrossRef
114.
A. di Masi, L. Leboffe, A. Sodo, G. Tabacco, R. Cesareo, M. Sbroscia, I. Giovannoni, C. Taffon, P. Crucitti, F. Longo, S. Manfrini, M.A. Ricci, P. Ascenzi, A. Crescenzi, A. Palermo, Metabolic profile of human parathyroid adenoma. Endocrine 67(3), 699–707 (2020)PubMedCrossRef
115.
I. Gromova, P. Gromov, N. Honma, S. Kumar, D. Rimm, M.L. Talman, V.T. Wielenga, J.M. Moreira, High level PHGDH expression in breast is predominantly associated with keratin 5-positive cell lineage independently of malignancy. Mol. Oncol. 9, 1636–1654 (2015)PubMedPubMedCentralCrossRef
116.
E. Mullarky, N.C. Lucki, R. Beheshti Zavareh, J.L. Anglin, A.P. Gomes, B.N. Nicolay, J.C. Wong, S. Christen, H. Takahashi, P.K. Singh, J. Blenis, J.D. Warren, S.M. Fendt, J.M. Asara, G.M. DeNicola, C.A. Lyssiotis, L.L. Lairson, L.C. Cantley, Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. Proc. Natl. Acad. Sci. U. S. A. 113, 1778–1783 (2016)
117.
M.E. Pacold, K.R. Brimacombe, S.H. Chan, J.M. Rohde, C.A. Lewis, L.J. Swier, R. Possemato, W.W. Chen, L.B. Sullivan, B.P. Fiske, S. Cho, E. Freinkman, K. Birsoy, M. Abu-Remaileh, Y.D. Shaul, C.M. Liu, M. Zhou, M.J. Koh, H. Chung, S.M. Davidson, A. Luengo, A.Q. Wang, X. Xu, A. Yasgar, L. Liu, G. Rai, K.D. Westover, M.G. Vander Heiden, M. Shen, N.S. Gray, M.B. Boxer, D.M. Sabatini, A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nat. Chem. Biol. 12, 452–458 (2016)PubMedPubMedCentralCrossRef
118.
J.M. Rohde, K.R. Brimacombe, L. Liu, M.E. Pacold, A. Yasgar, D.M. Cheff, T.D. Lee, G. Rai, B. Baljinnyam, Z. Li, A. Simeonov, M.D. Hall, M. Shen, D.M. Sabatini, M.B. Boxer, Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors. Bioorg. Med. Chem. 26, 1727–1739 (2018)PubMedPubMedCentralCrossRef
119.
J.E. Unterlass, A. Baslé, T.J. Blackburn, J. Tucker, C. Cano, M.E.M. Noble, N.J. Curtin, Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer. Oncotarget 9, 13139–13153 (2018)PubMedCrossRef
120.
The 5th RSC-BMCS fragment-based drug discovery meeting at Churchill College, Cambridge (UK) (2015)
121.
N. Fuller, L. Spadola, S. Cowen, J. Patel, H. Schönherr, Q. Cao, A. McKenzie, F. Edfeldt, A. Rabow, R. Goodnow, An improved model for fragment-based lead generation at AstraZeneca. Drug Discov. Today 21, 1272–1283 (2016)PubMedCrossRef
122.
S. Ravez, C. Corbet, Q. Spillier, A. Dutu, A.D. Robin, E. Mullarky, L.C. Cantley, O. Feron, R. Frédérick, α-Ketothioamide derivatives: a promising tool to interrogate phosphoglycerate dehydrogenase (PHGDH). J. Med. Chem. 60, 1591–1597 (2017)PubMedPubMedCentralCrossRef
123.
Q. Wang, M.V. Liberti, P. Liu, X. Deng, Y. Liu, J.W. Locasale, L. Lai, Rational design of selective allosteric inhibitors of PHGDH and serine synthesis with anti-tumor activity. Cell Chem. Biol. 24, 55–65 (2017)PubMedCrossRef
124.
J. Guo, X. Gu, M. Zheng, Y. Zhang, L. Chen, H. Li, Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase. Bioorg. Chem. 87, 16–22 (2019)PubMedCrossRef
125.
M. Zheng, J. Guo, J. Xu, K. Yang, R. Tang, X. Gu, H. Li, L. Chen, Ixocarpalactone A from dietary tomatillo inhibits pancreatic cancer growth by targeting PHGDH. Food Funct. 10(6), 3386–3395 (2019)PubMedCrossRef
126.
D. González-Mendoza, D. Ascencio-Martinez, A.H. Poox, V. Mendez-Trujillo, O. Grimaldo-Juarez, J.F.S. Hernández, L.C. Diaz, S.M.A. Marin, Phenolic compounds and physiochemical analysis of Physalis ixocarpa genotypes. Sci. Res. Essays 6, 3808–3814 (2011)CrossRef
127.
E. Mullarky, J. Xu, A.D. Robin, D.J. Huggins, A. Jennings, N. Noguchi, A. Olland, D. Lakshminarasimhan, M. Miller, D. Tomita, M. Michino, T. Su, G. Zhang, A.W. Stamford, P.T. Meinke, S. Kargman, L.C. Cantley, Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells. Bioorg. Med. Chem. Lett. 29, 2503–2510 (2019)PubMedPubMedCentralCrossRef
128.
H. Weinstabl, M. Treu, J. Rinnenthal, S.K. Zahn, P. Ettmayer, G. Bader, G. Dahmann, D. Kessler, K. Rumpel, N. Mischerikow, F. Savarese, T. Gerstberger, M. Mayer, A. Zoephel, R. Schnitzer, W. Sommergruber, P. Martinelli, H. Arnhof, B. Peric-Simov, K.S. Hofbauer, G. Garavel, Y. Scherbantin, S. Mitzner, T.N. Fett, G. Scholz, J. Bruchhaus, M. Burkard, R. Kousek, T. Ciftci, B. Sharps, A. Schrenk, C. Harrer, D. Haering, B. Wolkerstorfer, X. Zhang, X. Lv, A. Du, D. Li, Y. Li, J. Quant, M. Pearson, D.B. McConnell, Intracellular trapping of the selective phosphoglycerate dehydrogenase (PHGDH) inhibitor disrupts serine biosynthesis. J. Med. Chem. 62, 7976–7997 (2019)PubMedCrossRef
129.
E. Saiah, 3-phosphoglycerate dehydrogenase inhibitors and uses thereof. Patents. (2016)
130.
Q. Spillier, D. Vertommen, S. Ravez, R. Marteau, Q. Thémans, C. Corbet, O. Feron, J. Wouters, R. Frédérick, Anti-alcohol abuse drug disulfiram inhibits human PHGDH via disruption of its active tetrameric form through a specific cysteine oxidation. Sci. Rep. 9, 4737 (2019)PubMedPubMedCentralCrossRef
131.
J. Son, C.A. Lyssiotis, H. Ying, X. Wang, S. Hua, M. Ligorio, R.M. Perera, C.R. Ferrone, E. Mullarky, N. Shyh-Chang, Y. Kang, J.B. Fleming, N. Bardeesy, J.M. Asara, M.C. Haigis, R.A. DePinho, L.C. Cantley, A.C. Kimmelman, Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101–105 (2013)PubMedPubMedCentralCrossRef
132.
E.A. Zaal, W. Wu, G. Jansen, S. Zweegman, J. Cloos, C.R. Berkers, Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer Metab. 5, 7 (2017)PubMedPubMedCentralCrossRef
133.
C.K. Zogg, Phosphoglycerate dehydrogenase: potential therapeutic target and putative metabolic oncogene. J. Oncol. 2014, 524101 (2014)
134.
M.A. Reid, A.E. Allen, S. Liu, M.V. Liberti, P. Liu, X. Liu, Z. Dai, X. Gao, Q. Wang, Y. Liu, L. Lai, J.W. Locasale, Serine synthesis through PHGDH coordinates nucleotide levels by maintaining central carbon metabolism. Nat. Commun. 9, 5442 (2018)PubMedPubMedCentralCrossRef
Metadaten
Titel
3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment
verfasst von
Mingxue Li
Canrong Wu
Yueying Yang
Mengzhu Zheng
Silin Yu
Jinhui Wang
Lixia Chen
Hua Li
Publikationsdatum
18.03.2021
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 3/2021
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-021-00599-9

Weitere Artikel der Ausgabe 3/2021

Acetylation-stabilized chloride intracellular channel 1 exerts a tumor-promoting effect on cervical cancer cells by activating NF-κB

  • Original Article

Alterations in mucosa-associated microbiota in the stomach of patients with gastric cancer

  • Open Access
  • Original paper

COX2 confers bone marrow stromal cells to promoting TNFα/TNFR1β-mediated myeloma cell growth and adhesion

  • Original Article

Long non‐coding RNA LINC01137 contributes to oral squamous cell carcinoma development and is negatively regulated by miR-22-3p

  • Original Article

Functional relationship between CFTR and RAC3 expression for maintaining cancer cell stemness in human colorectal cancer

  • Original Article

Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non‐medullary thyroid cancer

  • Open Access
  • Original Article

Neu im Fachgebiet Pathologie

Overview of a comparative analysis of microsatellite instability and standard mismatch repair protein-deficiency tests in a large cancer cohort

  • Hauptreferate: Hauptprogramm der DGP

A retrospective analysis was carried out based on a large cancer patient cohort of our institute ( n  = 1306; collected from 2018 to 2023). dMMR was tested by four IHC reactions (MLH1 and PMS2 or MSH2 and MSH 6). Further, parallel pentaplex …

Molekulare Testung bei mesenchymalen Neoplasien: Was, wann und wie testen?

Mit dem weit verbreiteten Einsatz diverser molekularer Methoden in der histopathologischen Routinediagnostik hat die Tumorklassifikation in den letzten beiden Jahrzehnten signifikante Fortschritte gemacht. Dabei wurden zum einen zahlreiche …

Reconstructing 3D histological structures using machine learning (artificial intelligence) algorithms

  • Hauptreferate: Hauptprogramm der DGP

Artificial intelligence (AI) has recently been applied to pathological and medical image analysis with high sensitivity and specificity [ 1 , 2 ], aiding in various dental diagnostic techniques. The use of AI in image annotation has enhanced the …

Key considerations when implementing new diagnostic technologies in routine practice

  • Hauptreferate: Arbeitsgemeinschaften der DGP

This review explores several key considerations that are critical for implementing new diagnostic technologies into routine practice. These elements will provide a comprehensive guide for navigating the complexities of integrating cutting-edge …